Search NASA⌕ Search

SEARCH · Search NASA

Results for “AML”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5

Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML. Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib. FLT3 with quizartinib bound adopts an “Abl-like” inactive conformation with the activation loop stabilized in the “DFG-out” orientation and folded back onto the kinase domain. This conformation is similar to that observed for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop. The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant observed in many AML patients. This co-complex further provides a structural rationale for quizartinib-resistance mutations.

59 BASIC BIOLOGICAL SCIENCES↗

Concentrating Rare Earth Elements in Coal mine drainage Using Coal Combustion Products through Abandoned Mine Land Reclamation

Rare earth elements (REEs) (including scandium, yttrium and a group of 15 lanthanides) are often considered to be critical components in the productions of renewable energy hardware, electric vehicles, health care and military equipment, and consumer electronic products. The demand of REEs has been projected to be growing at an annual rate of 5-9% in the next 25 years. In 2011, the global demand of total rare earth oxides (REOs) was estimated to be approximately 105,000 tons, which is expected to grow to 210,000 tons by 2025. China overwhelmingly dominates the current worldwide rare earth productions but has strategically restricted its exports, causing significant instability for the global market. In response to the increasing demand for REEs and the supply dominance of China, identifying alternative sources of REEs has become a critical issue for the United States and other countries. Coal, coal ash, and coal mine drainage (CMD) are considered to be the alternative sources of REEs. In the U.S., high REE concentrations have been reported to be closely associated with coal deposits, including the Appalachian Basins. When surface and/or groundwater come in contact with geologic strata containing sulfide minerals exposed by coal mining, the accelerated oxidation of sulfide minerals in the presence of ferric iron and/or oxygen can produce sulfuric acid. The process promotes the weathering of REE-bearing rocks and minerals in the host geologic strata. Compared to average river water and seawater, the concentrations of REEs can be orders of magnitude higher in CMD. In this study, we demonstrated a trap-extract-precipitate (TEP) process that can effectively recover REEs from CMD. The three-stage TEP process uses alkaline industrial by-products to capture REEs from CMD and then applies an extraction/precipitation procedure to produce a feedstock that can be economically processed to produce marketable rare earth oxides. The alkaline industrial by-products tested in this study include the residual from a water softening process (DRWP sludge) and two types of stabilized flue gas desulfurization materials (sFGDs). sFGD material is a mixture of lime (CaO) and two coal combustion by-products, calcium sulfite FGD by-product and fly ash. The objectives of this study are to (1) validate the effectiveness and feasibility; (2) determine mechanisms controlling the rare earth recovery, (3) quantify the associated economic and environmental benefits, and (4) evaluate the full-scale application. To achieve these objectives, tasks to be carried out in this proposed project are organized into three phases. In the first phase, the research team collaborated with Ohio Department of Natural Resources, American Electric Power, The Wilds (a nonprofit wildlife conservation organization), and a private landowner to carry out field investigations aimed to screen and evaluate the seasonal changes of rare earths in the CMD discharges that have high recovery potentials. Next, the recovery of REEs from CMD was tested using a series of lab-scale column and batch tests under, respectively, percolation and completely mixed conditions. Results obtained from these lab-scale studies show that all three tested solids are very effective in retaining REEs. Over 98% of the CMD REEs that contacted the solids were captured before the solids exhausted their neutralization capacities. We also determined an extraction process using a non-acid, organic ligand extraction solution that can effectively remobilize the retained REEs from the spent solids (over 90%). The REE concentrate (>7.5 wt. % of total REEs) is then formed in an aeration process. The TEP process uses environmentally benign industrial by-products and a naturally-occurring organic ligand to mitigate CMD and recover REEs. Techno-economic analysis (TEA) and life-cycle assessment (LCA) was carried out in the third phase. The engineering-economic costs and net energy, net CO2 emissions, and water and other requirements were investigated to understand the economic and environmental implications of this process. This work uses mass and energy balances from laboratory-scale experiments to estimate the economic costs and environmental impacts. The results suggest that passive treatment systems that use DRWP sludge are preferred over those that use sFGD material, because of lower economic costs ($89,300/yr with a unit cost of $86/gT-REE vs. $89,800/yr, or $278/gT-REE) and improved environmental performance across all indicators from two different impact assessment methods. These differences are largely attributable to the larger capacity of DRWP sludge in the passive treatment application. We envision this TEP process can be integrated with abandoned mine land (AML) reclamation to create an approach that can add economic incentives for AML reclamation, remediate CMD discharge, and eliminate public safety hazards and threats to local environment and ecological systems posed by AMLs. It can restore lands and communities that are adversely impacted by legacy mining.

01 COAL, LIGNITE, AND PEAT↗

FY23 Status Report of the Activated Materials Laboratory at the Advanced Photon Source

The Activated Materials Laboratory (AML) is a new radiological facility located at the Advanced Photon Source (APS) in Argonne National Laboratory (ANL), adjacent to the high-energy x-ray microscopy (HEXM) beamline in the long beamline building (LBB) constructed under the APS-upgrade (APS-U) project. The AML is a centralized facility to facilitate the safe conduct of experiments on activated materials at the APS. This report provides an overview of the status of the AML as a Nuclear Science User Facilities (NSUF) partner user facility in preparation for the general user access in 2024 upon the commissioning of the APS-U beamlines. Specifically, details are provided regarding the laboratory's scope, functionality, components, operational blueprint, and data management approach. The plans on augmenting the instrumentation, refining operational procedures and developing a robust data management strategy for FY24 and beyond are also discussed.

43 PARTICLE ACCELERATORS↗

A new capability facilitating nuclear materials research: the Activated Materials Laboratory at the Advanced Photon Source

The Activated Materials Laboratory (AML), located in the Long Beamline Building (LBB) of the Advanced Photon Source (APS) of Argonne National Laboratory (ANL), serves as a centralized radiological facility for preparing radioactive samples for APS beamline experiments. The AML is equipped to receive shipments, handle open-form radioactive materials, encapsulate samples, and transport samples to-and-from beamline end-stations. The AML works closely with users and the APS radiological safety committee to make sure the safe conduct of experiments.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Calculation of the exchange ratio for the Adaptive Maneuvering Logic program

Improvements were made to the Adaptive Maneuvering Logic (AML) computer program, a computer-generated, air-to-air combat opponent. The primary improvement was incorporating a measure of performance, the exchange ratio, defined as the statistical measure of number of enemy kills divided by number of friendly losses. This measure was used to test a new modification of the AML's combat tactics. When the new version of the AML competed against the old version, the new version won with an exchange ratio of 1.4.

Neuman, F.↗

Improvements to the adaptive maneuvering logic program

The Adaptive Maneuvering Logic (AML) computer program simulates close-in, one-on-one air-to-air combat between two fighter aircraft. Three important improvements are described. First, the previously available versions of AML were examined for their suitability as a baseline program. The selected program was then revised to eliminate some programming bugs which were uncovered over the years. A listing of this baseline program is included. Second, the equations governing the motion of the aircraft were completely revised. This resulted in a model with substantially higher fidelity than the original equations of motion provided. It also completely eliminated the over-the-top problem, which occurred in the older versions when the AML-driven aircraft attempted a vertical or near vertical loop. Third, the requirements for a versatile generic, yet realistic, aircraft model were studied and implemented in the program. The report contains detailed tables which make the generic aircraft to be either a modern, high performance aircraft, an older high performance aircraft, or a previous generation jet fighter.

Burgin, George H.↗

Advanced manned launch systems

Advanced Manned Launch Systems (AMLS) studies underway at the NASA Langley Research Center are described. The AMLS studies have focused on investigating mission needs and identifying technologies, operational requirements, and life-cycle costs. Two-stage vertical take off rocket vehicles with significant levels of reusability are shown to be cost effective for moderate to high flight rates. All-hydrogen fuel vehicles are preferred over methane boosted systems for both operational and cost considerations. Drawings of possible AMLS design solutions are presented. Fully reusable, partially resusable, expendable stage and horizontal take off airbreather/rocket solutions are compared.

Talay, Theodore A.↗

Propulsion system requirements for reusable single-stage-to-orbit rocket vehicles

The conceptual design of a single-stage-to-orbit (SSTO) vehicle using a wide variety of evolutionary technologies has recently been completed as a part of NASA's Advanced Manned Launch System (AMLS) study. The employment of new propulsion system technologies is critical to the design of a reasonably sized, operationally efficient SSTO vehicle. This paper presents the propulsion system requirements identified for this near-term AMLS SSTO vehicle. Sensitivities of the vehicle to changes in specific impulse and sea-level thrust-to-weight ratio are examined. The results of a variety of vehicle/propulsion system trades performed on the near-term AMLS SSTO vehicle are also presented.

Stanley, Douglas O.↗

Advanced Manned Launch System

Several alternatives exist for the development of the next manned launch system. The Advanced Manned Launch System (AMLS), which represents a clean-sheet replacement for the Space Shuttle, faces competition from concepts such as (1) the Personnel Launch System, which would serve as a personnel transport to complement the Space Shuttle, and (2) an advanced version of the existing Space Shuttle. An AMLS system could begin operations sometime between 2005 and 2020, depending upon the level of national interest and support. It would probably demonstrate a payload capacity less than that of the Space Shuttle, although performance specifications are far from certain. Even the form of the AMLS is still under discussion. Design studies have considered a wide variety of options including all levels of hardware reusability; single-, dual- and multiple-staging; and airbreathing vs. rocket propulsion. An evaluation of the relative cost-effectiveness of these options is impossible without guidance regarding basic mission requirements such as total number of launches over the system's life cycle and the date required. The availability of more advanced technologies will enable single-stage-to-orbit (SSTO) designs that are in general not feasible using current technology.

Talay, Theodore A.↗

Propulsion requirements for reusable single-stage-to-orbit rocket vehicles

The conceptual design of a single-stage-to-orbit (SSTO) vehicle using a wide variety of evolutionary technologies has recently been completed as a part of NASA's Advanced Manned Launch System (AMLS) study. The employment of new propulsion system technologies is critical to the design of a reasonably sized, operationally efficient SSTO vehicle. This paper presents the propulsion system requirements identified for this near-term AMLS SSTO vehicle. Sensitivities of the vehicle to changes in specific impulse and sea-level thrust-to-weight ratio are examined. The results of a variety of vehicle/propulsion system trades performed on the near-term AMLS SSTO vehicle are also presented.

SEA LEVEL THRUST TO WEIGHT RAT↗

Magnet Architectures and Active Radiation Shielding Study (MAARSS)

This report describes the analysis of several magnetic radiation shield architectures and the spacecraft systems associated with them, such as quench detection, thermal management, and compensation coils. This work was performed as part of the NASA Institute of Advanced Concepts (NIAC) Grant Phase II effort. Because radiation exposure during long duration space missions poses a significant risk for crewed space-flight, Advanced Magnetic Lab, Inc. (AML) and NASA are studying magnetic radiation shielding, which may generate low-mass protection. Recent technological developments in high-temperature superconducting technology suggest the possibility of such shielding. This report analyzes some of the technical difficulties involved in such a system and identifies technology areas where further investment would be warranted. Most analysis was performed on a baseline configuration (8-meter diameter coils, with 1 tesla field). However, a baseline design with an expandable coil configuration (16 meter diameter coils, 1.5 tesla field) has a significant potential to increase shielding efficiency. The magnetic forces on the magnetic shield's components are large enough to require detailed structural design. Analysis of the thermal structural response of a yttrium-barium-copper-oxide (YBCO) high-temperature, superconducting (HTS) tape in a large-scale solenoid magnet showed that structural and thermal performance improved by replacing Hastelloy® with graphene in the tape. Integrating graphene into the high-strength fiber (HSF) support structure brings even greater benefits. The energy stored in a shield system's magnetic field must be safely dissipated if a quench-type failure occurs. Analysis of quench detection by fiber-optic thermal sensing and improvement of quench characteristics using graphene showed quench is manageable. Low-temperature superconductors can quench when subjected to movement, but lab tests of coil expansion testing showed that HTS materials do not quench when subject to the movement associated with coil expansion. Compensation coils are necessary to reduce the magnetic field in the crew habitat. Analysis showed that subdividing the compensation coil into individually controlled sections allows for a robust, adjustable system. AML analyzed the forces on an approaching capsule that were a result of eddy currents in its structure induced by its motion through the magnetic field from the coils. AML also analyzed coil-to-coil forces. Thermal control to maintain the HTS material at a suitable temperature is challenging. The sunshield technology review revealed a greater possibility of thermal insulation of the coils and use of passive cooling. The availability of suitable cryocoolers was also reviewed. A parametric graph estimating mass and shielding effectiveness for strength and thickness was developed, and allows spacecraft designers to assess the tradeoffs of using a magnetic radiation shield.

Spacecraft↗

Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series

Hereditary renal cell carcinoma syndromes (HRCCS) are characterized by the presence of pathogenic germline variants that predispose patients to renal cell carcinomas as well as additional extra-renal manifestations. The importance of identifying HRCCS patients cannot be overemphasized, as patients and their families can begin surveillance for syndrome-associated manifestations once identified. The present study is a retrospective clinical and morphologic review of 60 hereditary renal tumors from 30 HRCCS patients treated at our institution with either Von Hippel-Lindau disease (VHL), Birt-Hogg-Dubé syndrome (BHD), tuberous sclerosis complex (TSC), hereditary leiomyomatosis and renal cell cancer syndrome, or succinate dehydrogenase (SDH) deficiency syndrome. Hereditary renal cell carcinoma syndromes kidney tumors often demonstrate specific morphologic features, characteristic background changes in renal parenchyma, and extra-renal manifestations, which, when recognized by the pathologist, can trigger genetic testing referral for specific familial cancer syndromes. Our study demonstrates the majority of tumors were consistent with the anticipated clinicopathologic profile of renal tumors found within HRCCS patients, although we found some unique characteristics within this cohort including a case of clear cell papillary renal cell carcinoma within a VHL patient, and a unique renal tumor with tubulopapillary features present in a patient with a germline SDHD mutation. Additionally, although the literature reports the presence of epithelioid angiomyolipoma (AML) as a common occurrence in TSC patients, our cohort of 3 patients with AMLs demonstrated only classic features. The findings we describe facilitate pathologist-based recognition of HRCCS and can prompt genetic evaluation for relevant patients.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome

Monosomy 7 and interstitial deletions in the long arm of chromosome 7 (-7/7q-) is a common nonrandom chromosomal abnormality found frequently in myeloid disorders including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and juvenile myelomonocytic leukemia (JMML). Using a short probe-based microarray comparative genomic hybridization (mCGH) technology, we identified a common microdeletion cluster in 7q21.3 subband, which is adjacent to 'hot deletion region' thus far identified by conventional methods. This common microdeletion cluster contains three poorly characterized genes; Samd9, Samd9L, and a putative gene LOC253012, which we named Miki. Gene copy number assessment of three genes by real-time PCR revealed heterozygous deletion of these three genes in adult patients with AML and MDS at high frequency, in addition to JMML patients. Miki locates to mitotic spindles and centrosomes and downregulation of Miki by RNA interference induced abnormalities in mitosis and nuclear morphology, similar to myelodysplasia. In addition, a recent report indicated Samd9 as a tumor suppressor. These findings indicate the usefulness of the short probe-based CGH to detect microdeletions. The three genes located to 7q21.3 would be candidates for myeloid tumor-suppressor genes on 7q.

60 APPLIED LIFE SCIENCES↗

Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway

Highlights: Black-Right-Pointing-Pointer Metformin induces differentiation in NB4 and primary APL cells. Black-Right-Pointing-Pointer Metformin induces activation of the MEK/ERK signaling pathway in APL cells. Black-Right-Pointing-Pointer Metformin synergizes with ATRA to trigger maturation of NB4 and primary APL cells. Black-Right-Pointing-Pointer Metformin induces the relocalization and degradation of the PML-RAR{alpha} fusion protein. Black-Right-Pointing-Pointer The study may be applicable for new differentiation therapy in cancer treatment. -- Abstract: Recent studies have shown that metformin, a widely used antidiabetic agent, may reduce the risk of cancer development. In this study, we investigated the antitumoral effect of metformin on both acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) cells. Metformin induced apoptosis with partial differentiation in an APL cell line, NB4, but only displayed a proapoptotic effect on several non-M3 AML cell lines. Further analysis revealed that a strong synergistic effect existed between metformin and all-trans retinoic acid (ATRA) during APL cell maturation and that metformin induced the hyperphosphorylation of extracellular signal-regulated kinase (ERK) in APL cells. U0126, a specific MEK/ERK activation inhibitor, abrogated metformin-induced differentiation. Finally, we found that metformin induced the degradation of the oncoproteins PML-RAR{alpha} and c-Myc and activated caspase-3. In conclusion, these results suggest that metformin treatment may contribute to the enhancement of ATRA-induced differentiation in APL, which may deepen the understanding of APL maturation and thus provide insight for new therapy strategies.

60 APPLIED LIFE SCIENCES↗

All-trans retinoic acid combined with 5-Aza-2 Prime -deoxycitidine induces C/EBP{alpha} expression and growth inhibition in MLL-AF9-positive leukemic cells

Highlights: Black-Right-Pointing-Pointer We tested whether ATRA and 5-Aza affect AML cell differentiation and growth. Black-Right-Pointing-Pointer Cell differentiation and growth arrest were induced in MLL-AF9-expressing cells. Black-Right-Pointing-Pointer Increased expression of C/EBP{alpha}, C/EBP{epsilon}, and PU.1 were also observed. Black-Right-Pointing-Pointer MLL-AF4/AF5q31-expressing cells are less sensitive to ATRA and 5-Aza. Black-Right-Pointing-Pointer Different MLL fusion has distinct epigenetic properties related to RA pathway. -- Abstract: The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2 Prime -deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein {alpha} (C/EBP{alpha}) and c-Myc axis. After exposure to a combination of these agents, cell differentiation and growth arrest were significantly higher in human and murine MLL-AF9-expressing cells than in MLL-AF4/AF5q31-expressing cells, which were partly associated with increased expression of C/EBP{alpha}, C/EBP{epsilon}, and PU.1, and decreased expression of c-Myc. These findings indicate that MLL-AF9-expressing cells are more sensitive to ATRA and 5-Aza, indicating that different MLL fusion proteins possess different epigenetic properties associated with retinoic acid pathway inactivation.

60 APPLIED LIFE SCIENCES↗

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia

Acute myeloid leukemia is a poor prognosis cancer commonly stratified by genetic aberrations, but these mutations are often heterogeneous and don’t always predict therapeutic response. Here we combine transcriptomic, proteomic, and phosphoproteomic datasets with ex vivo drug sensitivity data to help understand the underlying pathophysiology of AML beyond mutations. We measured the proteome and phosphoproteome of 210 patients and combined them with genomics and transcriptomic measurements to identify four proteogenomic subtypes that complemented existing genetic subtypes. We then built a predictor to classify samples into subtypes based on 147 molecular features and mapped them to a ‘landscape’. Each region of this landscape corresponded to specific drug response patterns. We then built a drug response prediction model to identify drugs that target distinct subtypes. We can ultimately use these models to predict drug treatment response and prioritize treatments. Finally, we extended our models and mapped a series of cell lines representing various stages of quizartinib resistance into our subtype landscape, predicting and experimentally validating a switch in sensitivity to venetoclax to panobinostat, two drugs with very different mechanisms than quizartinib. Our results show how multi-omics data together with drug sensitivity data can inform therapy stratification and drug combinations in AML.

59 BASIC BIOLOGICAL SCIENCES↗

Degradation of AF1Q by chaperone-mediated autophagy

AF1Q, a mixed lineage leukemia gene fusion partner, is identified as a poor prognostic biomarker for pediatric acute myeloid leukemia (AML), adult AML with normal cytogenetic and adult myelodysplastic syndrome. AF1Q is highly regulated during hematopoietic progenitor differentiation and development but its regulatory mechanism has not been defined clearly. In the present study, we used pharmacological and genetic approaches to influence chaperone-mediated autophagy (CMA) and explored the degradation mechanism of AF1Q. Pharmacological inhibitors of lysosomal degradation, such as chloroquine, increased AF1Q levels, whereas activators of CMA, including 6-aminonicotinamide and nutrient starvation, decreased AF1Q levels. AF1Q interacts with HSPA8 and LAMP-2A, which are core components of the CMA machinery. Knockdown of HSPA8 or LAMP-2A increased AF1Q protein levels, whereas overexpression showed the opposite effect. Using an amino acid deletion AF1Q mutation plasmid, we identified that AF1Q had a KFERQ-like motif which was recognized by HSPA8 for CMA-dependent proteolysis. In conclusion, we demonstrate for the first time that AF1Q can be degraded in lysosomes by CMA. - Highlights: • Chaperone-mediated autophagy (CMA) is involved in the degradation of AF1Q. • Macroautophagy does not contribute to the AF1Q degradation. • AF1Q has a KFERQ-like motif that is recognized by CMA core components.

60 APPLIED LIFE SCIENCES↗